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OBJECTIVE — To estimate allele frequencies and the marginal and combined effects of novel
fasting glucose (FG)-associated single nucleotide polymorphisms (SNPs) on FG levels and on risk of
impaired FG (IFG) among non-Hispanic white, non-Hispanic black, and Mexican Americans.
RESEARCH DESIGN AND METHODS — DNA samples from 3,024 adult fasting par-
ticipants in the National Health and Nutrition Examination Survey (NHANES) III (1991–1994)
were genotyped for 16 novel FG-associated SNPs in multiple genes. We determined the allele
frequencies and inﬂuence of these SNPs alone and in a weighted genetic risk score on FG,
homeostasis model assessment of -cell function (HOMA-B), and IFG by race/ethnicity, while
adjusting for age and sex.
RESULTS — All allele frequencies varied signiﬁcantly by race/ethnicity. A weighted genetic
riskscore,basedon16SNPs,wasassociatedwitha0.022mmol/l(95%CI0.009–0.035),0.036
mmol/l (0.019–0.052), and 0.033 mmol/l (0.020–0.046) increase in FG levels per risk allele
among non-Hispanic whites, non-Hispanic blacks, and Mexican Americans, respectively. Ad-
justed odds ratios for IFG were 1.78 for non-Hispanic whites (95% CI 1.00–3.17), 2.40 for
non-Hispanic blacks (1.07–5.37), and 2.39 for Mexican Americans (1.37–4.14) when we com-
pared the highest with the lowest quintiles of genetic risk score (P  0.365 for testing hetero-
geneity of effect across race/ethnicity).
CONCLUSIONS — We conclude that allele frequencies of 16 novel FG-associated SNPs
vary signiﬁcantly by race/ethnicity, but the inﬂuence of these SNPs on FG levels, HOMA-B, and
IFG were generally consistent across all racial/ethnic groups.
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F
asting glucose (FG) is associated
with future risk of type 2 diabetes
and cardiovascular disease (1–3).
Impaired FG (IFG) (FG between 5.6 and
7.0 mmol/l), which is the high end of the
nondiabetic FG distribution, is also a risk
factor for type 2 diabetes and cardiovas-
cular disease (1,2,4,5). The prevalence of
type 2 diabetes and the complications as-
sociated with the disease vary signiﬁ-
cantly by race/ethnicity (6). Researchers
conducting recent genetic association
studies have used homeostasis model as-
sessment of -cell function (HOMA-B) to
identify several loci that inﬂuence levels
of FG and -cell function (7–9). A meta-
analysisofgenome-wideassociationdata,
by the Meta-Analysis of Glucose and In-
sulin-Related Traits Consortium
(MAGIC), recently conﬁrmed 16 com-
mon single nucleotide polymorphisms
(SNPs) associated with FG levels (10). In-
dex SNPs were in or near PROX1, G6PC2,
GCKR, ADCY5, SLC2A2, DGKB, GCK,
SLC30A8, GLIS3, ADRA2A, TCF7L2,
MTNR1B, FADS1, CRY2, MADD, and
C2CD4B (10). These associations were
discovered in white people of European
ancestry; the inﬂuence of these SNPs on
FG levels in nonwhite populations and
their allele frequencies in general-
population samples are unknown. The
frequencies of common disease-
associatedallelesdiscoveredbycandidate
gene or genome-wide association studies
(GWASs) can differ signiﬁcantly across
racial/ethnic groups (http://hapmap.ncbi.
nlm.nih.gov), and in some cases, the risk
allelewithinalocuswilldifferonthebasis
of race/ethnicity (11,12). Other studies
suggest that despite the substantial varia-
tions in allele frequencies, the genetic ef-
fects on common diseases are largely
consistent across racial/ethnic groups
(13). We addressed these concerns by
genotyping 16 conﬁrmed FG-associated
SNPs in adults who completed the Third
National Health and Nutrition Examina-
tion Survey (NHANES III; 1991–1994),
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large, representative sample of the U.S.
population that included non-Hispanic
whites, non-Hispanic blacks, and Mexi-
can Americans. We tested the hypotheses
that there is signiﬁcant racial/ethnic vari-
ation in 1) SNP risk (FG raising) allele
frequencies, 2) the marginal and com-
bined effects of these 16 SNPs on FG lev-
els and HOMA-B, and 3) the combined
effectofthese16riskSNPsonriskofIFG.
RESEARCH DESIGN AND
METHODS— The NHANES III used
a stratiﬁed multistage probability design
to obtain a nationally representative sam-
ple of the civilian, noninstitutionalized
U.S.population.IntheNHANESIII,each
survey participant had a household inter-
view and a physical examination; a subset
ofindividualshadfastingbloodsampling.
BloodspecimensforDNAcollectionwere
obtained from the NHANES III Phase 2
(1991–1994) participants aged 12
years. DNA lysates were created from cell
lines generated using Epstein-Barr–
transformed lymphocytes from these
bloodspecimens.Welimitedouranalyses
to nondiabetic participants who were
aged 20 years and had fasted between 8
and 23 h before blood collection. Of
3,517 eligible participants, we excluded
162 participants who self-identiﬁed their
race/ethnicity as “other” and also ex-
cluded 331 participants who either self-
reported diabetes or had a FG level 7.0
mmol/l or who had an oral glucose toler-
ance test (OGTT) 11.1mmol/l, which
left 3,024 participants in the study.
FG, HOMA-B, IFG, and diabetes
deﬁnitions
Plasma glucose levels were measured by
hexokinase (COBAS MIRA; Roche Diag-
nostics, Montclair, NJ). We used HOMA
as a surrogate measure of -cell function
(HOMA-B; calculated as [20  fasting in-
sulin{IU/ml}/FG{mmol/l}3.5])(14).
We deﬁned IFG as having a fasting
plasma glucose 5.6 mmol/l, but 7.0
mmol/landdiabetesasuseofantidiabetes
medications (including insulin) or a fast-
ing plasma glucose 7.0 mmol/l (4).
SNP genotyping
We genotyped 16 SNPs that were con-
ﬁrmedasassociatedwithFGlevelsamong
nondiabetic people of European ancestry
in the MAGIC GWAS (10). We used SNP
rs573225asaproxy(r
21.0inCEU)for
SNP rs560887 in G6PC2 and SNP
rs11558471 as a proxy (r
2  1.0 in CEU)
for SNP rs13266634 in SLC30A8. Geno-
typing was performed with the use of
iPLEX (Sequenom) (15). The minimum
call rate was 98.1%, and all SNPs were in
Hardy-Weinberg equilibrium (HWE) ac-
cording to the National Center for Health
Statistics criterion (if P  0.01 in two or
more race/ethnicity groups, HWE is
rejected).
Genetic risk score
We constructed a weighted genetic risk
score (GRS) to examine the combined ef-
fect of 16 SNPs on FG levels, HOMA-B,
and risk for IFG. We used the -coefﬁ-
cients from the published European an-
cestry GWASs of these FG-associated
SNPs (10). We multiplied these -coefﬁ-
cientsby0,1,or2,accordingtothenum-
ber of risk alleles carried by each
individual, and then summed them. To
facilitate the comparison with the simple
GRS (summing the number of risk al-
leles), we divided the score by 0.948
(twice the sum of the -coefﬁcients) and
multiplied by 32 (total number of alleles)
(16). Although a number of SNPs did not
show signiﬁcant association with FG or
HOMA-B in the NHANES III, we as-
sumed,onthebasisofGWASresults,that
each SNP is independently associated
with FG for computation of a weighted
GRS. This assumption might not be ap-
propriate if an index SNP is correlated
with the causal SNP in the discovery pop-
ulation but not so in other racial/ethnic
groups due to differences in linkage dis-
equilibriumpatterns(17).Weusedanad-
ditive genetic model for each SNP and
applied a linear weighting of 0, 1, or 2 to
genotypescontaining0,1,or2riskalleles
(16). We ﬁt the weighted GRS as a con-
tinuous variable and categorized it into
quintiles in multivariate analyses. In pre-
senting the results, we rounded the
weighted GRS to the whole number.
Statistical analysis
Wecalculatedweightedallelefrequencies
and their 95% CIs, stratiﬁed by race/
ethnicity (non-Hispanic white, non-
Hispanic black, and Mexican American)
using the NHANES sample weights. We
carried out HWE tests for each genetic
variant for each racial/ethnic group. To
test for differences in allele frequencies,
we pooled all racial/ethnic groups and
used 
2 to test the differences across the
racial/ethnic groups. We used linear re-
gression modeling to evaluate the rela-
tionship between 16 SNPs and FG levels
and HOMA-B, adjusted for age and sex.
Weexaminedtheadjustedmarginaleffect
on FG by including one SNP at a time in
the model for each racial/ethnic group.
SNPs were coded as 0, 1, or 2 for those
who were noncarriers, heterozygous, or
homozygous for the risk (FG raising) al-
leles, respectively. We modeled the GRS
inasimilarfashionbytestingassociations
of a per–risk allele increase with FG. For
the GRS models, we calculated adjusted
R
2, with and without the GRS to deter-
mine the explained variance, by adding
the GRS in the models for each racial/
ethnic group. We tested for homogeneity
of effects of these SNPs in marginal and
GRS models across race/ethnicity by in-
cluding the interaction terms of SNP or
GRS with race/ethnicity in the regression
models using the pooled dataset and re-
ported the associated P value.
We used age- and sex-adjusted logis-
tic regression to evaluate the association
of the GRS with prevalence of IFG for
eachracial/ethnicgroup.Wemodeledthe
GRS to test the association of a per–risk
allele increase with odds of IFG. We also
categorized the GRS into quintiles to ex-
amine the trend of effect on risk of IFG.
We tested for homogeneity of the GRS
effect on IFG across race/ethnicity by in-
cluding the interaction term using the
pooled dataset. Statistical tests, using lin-
ear or logistic regression modeling, were
based on Satterthwaite adjusted-F statis-
tics.Alltestsweretwosided,andaPvalue
of 0.05 at each locus or the GRS was
considered signiﬁcant. To avoid nonre-
sponse bias among NHANES III partici-
pants for whom DNA were available, the
sample weights were recalculated for the
NHANES III DNA dataset by using previ-
ously described methods (18). We used
SUDAAN(version10.0)andSAS(version
9.2; SAS Institute, Cary, NC) statistical
software for our analyses to account for
the complex sampling design.
RESULTS— There were 3,024 indi-
viduals available for this study, including
1,225 non-Hispanic white, 897 non-
Hispanic black, and 902 Mexican Ameri-
can participants. Compared with other
groups, FG was higher among Mexican
Americans, and HOMA-B was lower
among non-Hispanic whites (Table 1).
Allele frequencies of FG genetic
variants
All allele frequencies (16 SNPs) were sig-
niﬁcantly different across racial/ethnic
groups (P  0.05). Risk allele frequencies
varied from 17.1% (rs4607517, GCK)t o
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Hispanic whites, from 7.9% (rs10830963,
MTNR1B) to 93.7% (rs7944584, MADD)
among non-Hispanic blacks, and from
18.0% (rs7903146 (TCF7L2) to 86.5%
(rs11920090, SLC2A2) among Mexican
Americans (Table 2) (online appendix Ta-
ble 1, available at http://care.diabetes
journals. org/cgi/content/full/dc10-0898/
DC1).
Marginal effect of genetic variants on
FG and HOMA-B
We observed three SNPs (rs573225,
rs780094, and rs11558471) that were
signiﬁcantly associated with FG levels
among non-Hispanic whites, one SNP
(rs10830963) among non-Hispanic blacks,
and three variants (rs573225, rs4607517,
and rs10830963) among Mexican Ameri-
cans (online appendix Tables 2 and 3).
However, the majority of -coefﬁcients (37
of 48) showed positive associations in the
expecteddirectionwithFGlevelsamongall
threeracial/ethnicgroups.Wefoundnoev-
idenceofheterogeneityeffectsoftheseSNPs
onFGlevelsacrossracial/ethnicgroups,ex-
cept for rs11885122 for which non-
Hispanic whites had lower FG and non-
Hispanic blacks and Mexican Americans
had higher FG levels (P  0.009). Gener-
Table 1—Characteristics of participants by race/ethnicity, NHANES III DNA Bank (1991–1994)
Variables
Weighted distribution by race/ethnicity*
Non-Hispanic white Non-Hispanic black Mexican P value†
n 1,225 897 902
FG (mmol/l)
Mean (95% CI) 5.17 (5.14–5.19) 5.16 (5.11–5.21) 5.30 (5.24–5.36) 0.001
HOMA-B (n  3,017)
Mean (95% CI) 121.5 (109.4–133.6) 155.1 (144.3–165.9) 144.0 (134.6–153.4) 0.008
Age (years)
Mean (SEM) 43.7 (0.7) 39.6 (0.7) 35.5 (0.7) 0.001
Sex (% 95% CI	)
Male 48.6 (44.9–52.3) 44.3 (41.2–47.4) 53.0 (50.7–55.3)
Female 51.4 (47.7–55.1) 55.7 (52.6–58.8) 47.0 (44.7–49.3) 0.001
BMI (kg/m
2)( %95% CI	)
25 45.0 (41.9–48.2) 33.4 (29.7–37.4) 32.2 (28.5–36.2)
25 to 30 34.4 (30.9–38.1) 36.4 (33.6–39.3) 41.6 (37.7–45.7)
30 20.6 (17.9–23.6) 30.2 (27.2–33.2) 26.1 (22.8–29.8) 0.001
Proportion of non-Hispnic white, non-Hispanic
black, and Mexican Americans (95% CI) 81.9 (77.7–85.4) 12.1 (9.0–16.0) 6.0 (4.3–8.3)
*For continuous variables, the means were adjusted for age and sex. †P values were tests for the differences across race/ethnicity groups and are based on
Satterthwaite adjusted F statistics for the continuous variables and 
2 for the categorical variables.
Table 2—Weighted-risk (FG raising) allele frequencies of 16 FG-associated SNPs by race/ethnicity, NHANES III DNA Bank (1991–1994)
SNP Chromosome Nearest gene
Risk allele
(effect/other)†
Risk allele frequency % (95% CI)*
Non-Hispanic
white
Non-Hispanic
black
Mexican
American
rs340874 1 PROX1 C/T 52.4 (48.9–55.9) 21.9 (19.2–24.8) 41.2 (38.2–44.2)
rs573225 2 G6PC2 A/G 69.9 (67.7–72.1) 92.6 (90.9–93.9) 82.6 (79.8–85.1)
rs780094 2 GCKR C/T 58.3 (55.9–60.6) 80.8 (78.7–82.7) 65.1 (62.1–67.9)
rs11708067 3 ADCY5 A/G 77.8 (75.4–80.0) 85.3 (83.2–87.2) 72.4 (69.8–75.0)
rs11920090 3 SLC2A2 T/A 85.4 (83.8–86.8) 66.0 (63.8–68.1) 86.5 (84.0–88.7)
rs2191349 7 DGKB T/G 54.7 (52.7–56.6) 57.9 (55.8–59.9) 41.9 (38.2–45.7)
rs4607517 7 GCK A/G 17.1 (15.3–18.9) 9.4 (7.6–11.7) 21.8 (19.8–23.8)
rs11558471 8 SLC30A8 A/G 69.0 (65.6–72.2) 88.7 (86.9–90.3) 72.9 (70.7–75.0)
rs7034200 9 GLIS3 A/C 51.3 (48.9–53.7) 62.6 (60.3–64.8) 52.3 (50.4–54.2)
rs10885122 10 ADRA2A G/T 86.1 (84.7–87.4) 34.9 (32.6–37.2) 82.9 (80.8–84.9)
rs7903146 10 TCF7L2 T/C 29.1 (26.8–31.6) 26.7 (25.3–28.2) 18.0 (16.3–19.8)
rs10830963 11 MTNR1B G/C 28.0 (25.8–30.3) 7.9 (6.4–9.8) 21.1 (18.5–24.0)
rs174550 11 FADS1 T/C 66.5 (63.9–69.0) 89.8 (87.6–91.6) 39.2 (34.5–44.1)
rs11605924 11 CRY2 A/C 48.3 (45.5–51.2) 85.4 (83.3–87.3) 50.0 (46.5–53.6)
rs7944584 11 MADD A/T 71.4 (68.9–73.8) 93.7 (91.7–95.3) 84.3 (82.0–86.3)
rs11071657 15 C2CD4B A/G 64.2 (62.0–66.4) 86.4 (83.7–88.6) 49.2 (46.1–52.3)
*All SNPs were in HWE. †FG-raising allele (effect) is denoted ﬁrst.
Genetic variants and fasting glucose levels
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16SNPswereseenforHOMA-B(onlineap-
pendix Table 2).
Combined effects of genetic variants
on FG and HOMA-B
The number of risk alleles at 16 SNPs
ranged from 10 to 27 (median 19), 12 to
26(median20),and10to26(median18)
among non-Hispanic whites, non-
Hispanicblacks,andMexicanAmericans,
respectively. For the weighted GRS, the
corresponding numbers were 8–27 (me-
dian 17), 10–24 (median 18), and 9–26
(median 17), respectively. The GRS was
normally distributed in all three racial/
ethnicgroups(Kolmogorov-SmirnovP
0.001) (online appendix Fig. 1). FG in-
creased signiﬁcantly across the quintile of
GRS for all racial/ethnic groups. Each ad-
ditional risk allele in the score was asso-
ciated with a 0.022, 0.036, and 0.033
mmol/l increase in FG among non-
Hispanic whites, non-Hispanic blacks,
andMexicanAmericans,respectively(Ta-
ble 3). There was no evidence of a differ-
ent effect of the GRS on FG levels or
HOMA-B across race/ethnicity (P 
0.291 and 0.637 for testing heterogeneity
of the GRS on FG levels and HOMA-B
across race/ethnicity, respectively). In a
model including age and sex, the GRS ex-
plained more of the total variation in FG
in Mexican Americans and in non-
Hispanic blacks than in non-Hispanic
whites (Table 3). Generally, similar pat-
terns of associations of these 16 SNPs
were seen for HOMA-B (Table 3).
Combined effects of genetic variants
on IFG
The prevalence of IFG, adjusted for age
and sex, was lowest among non-Hispanic
blacksandhighestamongMexicanAmer-
icans. The adjusted odds ratios for IFG
were highest among Mexican Americans,
comparing people in the highest with
those in the lowest quintiles of the GRS
for all racial/ethnic groups (Table 4) (on-
line appendix Fig. 2). There was no evi-
dence of a different effect of the GRS on
risk for IFG across race/ethnicity (P 
0.365 for testing heterogeneity across
race/ethnicity). Each additional allele was
associated with a signiﬁcant increased
risk of IFG for all racial/ethnic groups.
CONCLUSIONS — Our ﬁndings
show that risk allele frequencies of the in-
cludedSNPsdiscoveredinpopulationsof
European ancestry differed signiﬁcantly
by racial/ethnic group, consistent with
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estimates (11,12). However, despite sig-
niﬁcant variations in allele frequencies,
the patterns of inﬂuence of these SNPs on
FG levels, HOMA-B, and IFG were gener-
ally consistent across racial/ethnic
groups. A GRS derived by the combina-
tion of these 16 SNPs was weakly, yet sig-
niﬁcantly, associated with an increase in
FG levels, a decrease in HOMA-B, and an
increase in risk for IFG in all racial/ethnic
groups. Our ﬁndings suggest that the ge-
netic variants at these glycemic loci, dis-
covered in the white population of
European ancestry, also contribute to the
elevated FG and reduced HOMA-B
among non-Hispanic blacks and Mexican
Americans.
The 16 FG-associated SNPs are lo-
cated in or near genes involved in multi-
ple biological pathways (10). Some of
these SNPs were also associated with type
2 diabetes (19–21), and a few have been
replicated in non-European populations
(22,23). Our study includes the most up-
dated SNPs associated with FG and esti-
mates their frequencies and effects in a
nationally representative sample of the
U.S. population. Our results suggest that
with an adequate sample size (not neces-
sarily as large as for a GWAS), these FG-
associated SNPs would likely be
replicated among non-Hispanic blacks
and Mexican Americans.
Although FG levels seem tightly reg-
ulated within a narrow range by a feed-
back mechanism that targets a particular
FG set point for each person (24), FG lev-
els vary substantially among nondiabetic
populations,andanestimated25–40%of
the variation may be explained by genetic
factors (7). Many studies have suggested
thatelevatedFGlevelsareassociatedwith
multiplehealthconditions,includingrisk
fortype2diabetesandcardiovasculardis-
eases(1,2,4,5).Thesediseasesrepresenta
major burden of disease in many popula-
tions(25).Identiﬁcationofpopulationsat
high risk of developing type 2 diabetes
has great public health importance. Our
ﬁndings suggest that a GRS, on the basis
of these FG-associated SNPs, is signiﬁ-
cantly associated with IFG, but it is un-
clear if these SNPs can improve
predictions for risks of type 2 diabetes or
cardiovasculardiseaseinthegeneralpop-
ulation.Furtherstudiesarealsoneededto
examinethepossibleassociationsofthese
SNPs with type 2 diabetes and cardiovas-
cular diseases in different races and
ethnicities.
However, the combined effects of
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2374 DIABETES CARE, VOLUME 33, NUMBER 11, NOVEMBER 2010 care.diabetesjournals.orgthese SNPs explain only a small percent-
age of the total variations in FG levels and
HOMA-B (3%), suggesting that addi-
tional loci exist. These loci may be com-
mon genetic variants with small effects,
rare variants with larger effects, or vari-
ants that strongly interact with each other
or with environmental factors (in which
the number and effect size remain un-
known). These interactions are undoubt-
edlyimportantbutcomplicatedtomodel;
their exploration is beyond the scope of
our study.
The major strengths of our study in-
clude the availability of FG and HOMA-B
measurements from a nationally repre-
sentative sample of the U.S. population
withmultipleracial/ethnicgroupsandthe
genotyping of the 16 most updated FG-
associated SNPs. There are several limita-
tions of our study. First, these FG-
associated SNPs were discovered among
populations of European ancestry and
maybeproxiesforthecausalvariants.Itis
well known that linkage disequilibrium
patterns vary signiﬁcantly by race/
ethnicity (17), and it is unclear if linkage
disequilibrium might break down for
some of these SNPs in other racial/ethnic
groups (online appendix Fig. 3). Addi-
tional ﬁne mapping in all three race/
ethnic groups is needed. Second, we
replicated a limited number of SNPs—
even among non-Hispanic whites—that
were signiﬁcantly associated with FG lev-
els or HOMA-B in the NHANES III. As
indicatedinthepowercalculation(online
appendix), we had limited sample size to
detect an effect size of 0.07 mmol/l in
FGperalleleforeachindividualSNP.The
mostlikelyexplanationforthelackofsig-
niﬁcant association was the limited sam-
ple size of fasting individuals from the
NHANES III. Since these were GWAS-
conﬁrmed, FG-associated SNPs (at least
among non-Hispanic whites), we in-
cluded all SNPs in our analysis. However,
using the GRS as a continuous variable,
we have adequate power to detect an ef-
fect size as low as 0.016 mmol/l per risk
allele. When including only the 11 SNPs
that showed the expected direction of ef-
fectsforFGandHOMA-B,theassociation
of the GRS appeared to be stronger,
though the patterns remained unchanged
(results not shown). At least for non-
Hispanic whites, a larger sample size
would not likely change the conclusions
since the majority of the SNPs’ effects are
in the expected direction, consistent with
studies in European populations (10).
Third, we calculated the weighted GRS
for the three racial/ethnic groups on the
basis of the published -coefﬁcients from
populations of European ancestry be-
cause of a lack of estimates for other
racial/ethnic groups (10). These -coefﬁ-
cients might not be appropriate for other
populations. However, the consistent ef-
fects of the GRS on FG, HOMA-B, and
IFG across racial/ethnic groups suggest
that the weighting was not totally inap-
propriate in these populations. In addi-
tion, the pattern of association between
weighted and unweighted GRS on FG,
HOMA-B, and IFG were consistent (on-
line appendix Tables 4 and 5).
Insummary,ourresultssuggestthat
the allele frequencies of FG-associated
SNPs varied signiﬁcantly by race/
ethnicity. However, the patterns of
combined effects of these SNPs on FG
levels and HOMA-B were consistent
across the different racial/ethnic
groups. A GRS that was based on 16
SNPs was signiﬁcantly associated with
risk of IFG among all racial/ethnic
groups, which may make it useful for
the identiﬁcation of people who are at
high risk for developing diabetes.
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